Patents Assigned to DKFZ Deutsches Krebsforschungszentrum
-
Patent number: 11320438Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.Type: GrantFiled: October 31, 2016Date of Patent: May 3, 2022Assignees: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITAT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
-
Publication number: 20180246118Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.Type: ApplicationFiled: October 31, 2016Publication date: August 30, 2018Applicants: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITÄT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
-
Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG) or (D)-2-hydroxyadipic acid
Patent number: 9487815Abstract: The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject.Type: GrantFiled: March 1, 2013Date of Patent: November 8, 2016Assignees: DKFZ Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität HeidelbergInventors: Jörg Balss, Stefan Pusch, Andreas Von Deimling, Wolfgang Buckel -
Publication number: 20160250316Abstract: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.Type: ApplicationFiled: February 23, 2016Publication date: September 1, 2016Applicant: DKFZ Deutsches KrebsforschungszentrumInventors: Martin MUELLER, Ivonne RUBIO, Massimo TOMMASINO, Simone OTTONELLO, Angelo BOLCHI
-
Patent number: 9303082Abstract: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.Type: GrantFiled: December 17, 2009Date of Patent: April 5, 2016Assignee: DKFZ Deutsches KrebsforschungszentrumInventors: Martin Mueller, Ivonne Rubio, Massimo Tommasino, Simone Ottonello, Angelo Bolchi
-
Patent number: 9034604Abstract: The present invention relates to a method for determining contaminations in a cell culture sample comprising the steps of: a) contacting a sample of a cell culture suspected to comprise contaminations with a composition comprising oligonucleotides under conditions which allow for amplification of polynucleotides, wherein said oligonucleotides comprise oligonucleotides of at least three different groups of oligonucleotides, and b) determining the contaminations based on the amplified polynucleotides obtained by using the oligonucleotide groups of step (a). Moreover, the invention relates to a composition comprising an oligonucleotide mixture. Further encompassed by the present invention is a composition comprising a probe oligonucleotide mixture. Finally, the present invention also relates to kits comprising said oligonucleotide mixtures.Type: GrantFiled: March 5, 2009Date of Patent: May 19, 2015Assignee: DKFZ Deutsches KrebsforschungszentrumInventors: Markus Schmitt, Michael Pawlita
-
Patent number: 8992923Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.Type: GrantFiled: February 22, 2013Date of Patent: March 31, 2015Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Oeffentlichen RechtsInventors: Hai-Kun Liu, Guenther Schuetz
-
MEANS AND METHODS FOR THE DETERMINATION OF (D)-2-HYDROXYGLUTARATE (D2HG) OR (D)-2-HYDROXYADIPIC ACID
Publication number: 20150044716Abstract: The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject.Type: ApplicationFiled: March 1, 2013Publication date: February 12, 2015Applicants: DKFZ Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität HeidelbergInventors: Jörg Balss, Stefan Pusch, Andreas Von Deimling, Wolfgang Buckel -
Patent number: 8598126Abstract: The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification.Type: GrantFiled: April 7, 2009Date of Patent: December 3, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des offentlichen RechtsInventors: Felix Hoppe-Seyler, Karin Hoppe-Seyler, Susanne Kintscher
-
Patent number: 8568994Abstract: The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen RechtsInventors: Peter Altevogt, Sascha Keller
-
Publication number: 20130225530Abstract: The present invention relates to a pharmaceutical composition for use as a medicament for the treatment or prophylaxis of cardiac hypertrophy, comprising at least one compound of formula (I), wherein: R1 is e.g. hydrogen, —CH3, R2 is e.g. hydrogen, —CH3, R4 is hydrogen, —OH, —NH2; R5 is hydrogen, —OH; R6 is hydrogen, —OH; R3 is e.g. —OCH3 or a pharmaceutically acceptable salt, and at least one pharmaceutical excipient.Type: ApplicationFiled: July 6, 2011Publication date: August 29, 2013Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Min Li-Weber, H. Peter Krammer, Gernot Polier
-
Publication number: 20130189267Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.Type: ApplicationFiled: February 22, 2013Publication date: July 25, 2013Applicant: DKFZ Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen RechtsInventor: DKFZ Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen Rechts
-
Patent number: 8404657Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.Type: GrantFiled: November 18, 2008Date of Patent: March 26, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Oeffentlichen RechtsInventors: Hai-Kun Liu, Günther Schütz
-
Patent number: 8361955Abstract: The present invention is concerned with the therapy of neuroblastoma and related diseases. Specifically, the present invention relates to a method for treating or preventing neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4). Preferably, said BMP4 is applied together with chemotherapy and/or radiation therapy.Type: GrantFiled: February 4, 2009Date of Patent: January 29, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen RechtsInventors: Hedwig Elisabeth Deubzer, Olaf Witt
-
Patent number: 8219325Abstract: The invention relates to a method for determining the ratio of two distinct target-peptides or polynucleic acids comprising: a) obtaining a sample containing said two distinct target-peptides or polynucleic acids, b) providing a precursor-peptide or precursor-polynucleic acid, comprising the two distinct target-peptides or -polynucleic acids in a known ratio, wherein the two distinct target-peptides or -polynucleic acids are connected by a cleavage site, c) cleaving the precursor-peptide or precursor-polynucleic acid at the cleavage site to obtain a standard with the known ratio of the two distinct target-peptides or -polynucleic acids, d) detecting a signal of each distinct target-peptide or -polynucleic acid of the standard in an analyzer, comparing the signals with the known ratio and determining a correction factor, e) detecting the signal of each distinct target-peptide or -polynucleic acid of the sample in the analyzer and f) determining the ratio of the two distinct target-peptides or -polynucleic acidType: GrantFiled: April 25, 2007Date of Patent: July 10, 2012Assignee: DKFZ Deutsches Krebsforschungszentrum Stiftung Des Offentlichen RechtsInventor: Wolf Dieter Lehmann
-
Patent number: 8202694Abstract: The present invention relates to a composition comprising an oligonucleotide mixture. Moreover, the present invention relates to the use of said oligonucleotide mixture for diagnosing different HPV genotypes in a sample of a subject. Further encompassed is a method for diagnosing different HPV genotypes in a sample of a subject and a kit carrying out said method.Type: GrantFiled: August 26, 2008Date of Patent: June 19, 2012Assignee: DKFZ Deutsches Krebsforschungszentrum Stiftung des Öffentlichen RechtsInventors: Markus Schmitt, Tim Waterboer, Michael Pawlita
-
Publication number: 20120107797Abstract: The present invention is concerned with the provision of diagnostic means and methods. Specifically, it relates to a composition comprising oligonucleotides selected from at least two different groups of oligonucleotides, said groups comprising at least one pair of oligonucleotides being capable of specifically amplifying polynucleotides comprised by a Bovine Papillomavirus (BPV), said BPV being selected from the group consisting of BPV-1, BPV-2, BPV-3, BPV-4, BPV-5, BPV-6, BPV-7, BPV-8, BPV-9, BPV-10, and BAPV-11 as well as uses based on said composition and kits comprising it. Moreover, contemplated is a method for the simultaneous detection and/or identification of BPV types in a sample.Type: ApplicationFiled: March 17, 2010Publication date: May 3, 2012Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES OFFENTLICHEN RECHTSInventors: Markus Schmitt, Martin Müller
-
ASSEMBLY OF ABSOLUTELY QUANTIFIED PEPTIDE AND PHOSPHOPEPTIDE SOLUTIONS VIA ELEMENT MASS SPECTROMETRY
Publication number: 20120003680Abstract: The present invention relates generally to the fields of analytics of proteins and peptides. More particularly, the invention concerns generation of an absolutely quantified reference peptide or protein solution via element mass spectrometry. Furthermore, the invention relates to the absolute quantification of phosphopeptides and peptides by the use of an absolutely quantified peptide solution.Type: ApplicationFiled: January 11, 2010Publication date: January 5, 2012Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÕFFENTLICHEN RECHTSInventors: Wolf Dieter Lehmann, Nico Zinn, Bettina Hahn -
Patent number: 8041414Abstract: The invention relates to a dual-modality imaging system and a method for dual-modality imaging of an imaged object, wherein a magnetic resonance imaging (MRI) apparatus for acquiring MRI data and at least one optical imaging detector for acquiring optical imaging data are arranged to acquire the MRI data and the optical imaging data of the imaged object (10) simultaneously, the at least one optical imaging detector being a non-contact optical imaging detector.Type: GrantFiled: September 4, 2007Date of Patent: October 18, 2011Assignee: DKFZ Deutsches Krebsforschungszentrum Stiftung Des Offentlichen RechtsInventors: Joerg Peter, Michael Bock, Reiner Umathum
-
Publication number: 20110250166Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.Type: ApplicationFiled: November 20, 2009Publication date: October 13, 2011Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Min Li-Weber, Peter H. Krammer